The first therapeutical trials using conventional immunosuppressive agents in recent onset type-1 diabetes mellitus have shown that such an approach can be efficient. However, remissions have remained inconstant and, when induced, transient. New approaches are being developed in experimental models in animals. Some, especially attempts to induce immune tolerance per os, could find rapid applications in the human.